Trial Profile
A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Cetrelimab (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 Aug 2023 Planned End Date changed from 31 May 2026 to 28 Feb 2026.
- 16 Aug 2023 Planned primary completion date changed from 31 May 2025 to 28 Feb 2025.
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.